Aug 30 (Reuters) - Pfizer Inc said on Monday its drug to treat patients with moderate to severe atopic dermatitis met main goal in a late-stage study and was statistically superior compared to rival from Regeneron. (Reporting by Dania Nadeem in Bengaluru)